--- title: "Silexion Therapeutics (SLXN) news: reverse split and delisting" url: "https://aibio.space/companies/silexion-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SLXN reverse split, delisting, going concern, offering, Nasdaq notice and lawsuit news: Silexion shareholders back a 1-for-24 reverse split and more…" --- SLXN Silexion Therapeutics Corp NASDAQ · Israel # Silexion Therapeutics (SLXN) news SLXN reverse split, delisting and going concern news Financings · 2026-10-28 ## [Silexion files to register resale of up to 8,813,531 shares](https://aibio.space/news/silexion-files-register-resale-up-8-813-531-shares/) Silexion's S-3 registers resale of up to 8,813,531 ordinary shares by selling shareholders from an August warrant inducement, a converted sponsor note and stock paid to LifeSci Advisors. The filing also discloses a June 2026 complaint from the sponsor, which seeks repayment of $3.433 million. ## Latest Silexion Therapeutics news 1. 2026-10-26 Listings [Silexion shareholders back a 1-for-24 reverse split and more authorized shares](https://aibio.space/news/silexion-shareholders-back-1-24-reverse-split-more-authorized-shares/) Silexion shareholders approved a 500,000,000-share increase in authorized capital and a reverse split. The board chose 1-for-24 from a range of 1-for-15 to 1-for-25. Holders of about 18.6% of shares attended the reconvened meeting, which the articles treat as a quorum. 2. 2026-10-19 Listings [Silexion adjourns vote on 500 million new shares and reverse split to October 26](https://aibio.space/news/silexion-adjourns-vote-500-million-new-shares-reverse-split-october-26/) The company says it needs both measures to protect its Nasdaq listing, with 14,473,292 shares already outstanding against 15,900,000 authorized. Shareholders rejected smaller versions in September. 3. 2026-09-28 Financings [Silexion cuts warrant price to $0.2603 to raise about $0.84 million](https://aibio.space/news/silexion-cuts-warrant-price-0-2603-raise-about-0-84-million/) Holders exercising 3,216,928 existing warrants receive 6,433,856 new warrants that cannot be used until shareholders approve more authorized shares. 4. 2026-09-25 Listings [Silexion adds bid-price deficiency to pending Nasdaq panel review](https://aibio.space/news/silexion-adds-bid-price-deficiency-pending-nasdaq-panel-review/) A Nasdaq hearings panel is already weighing a delisting over low shareholders' equity. The closing bid price has been below $1.00 for 30 consecutive business days. 5. 2026-08-14 Distress [Silexion had $2.2 million in cash at June 30 and flags going-concern doubt](https://aibio.space/news/silexion-had-2-2-million-cash-june-30-flags-going-concern-doubt/) Management said cash would last through the fourth quarter of 2026. The company has leaned on at-the-market sales and small offerings, and a Nasdaq delisting notice followed on August 18. 6. 2026-08-13 Financings [Silexion raises $2.5 million in public offering of shares and warrants at $0.65](https://aibio.space/news/silexion-raises-2-5-million-public-offering-shares-warrants-0-65/) The best-efforts deal closed August 13, 2026. Silexion also converted $750,001 of debt owed to its former SPAC sponsor into shares at the offering price. 7. 2026-06-22 Legal [Former SPAC sponsor sues Silexion in Tel Aviv over note conversions](https://aibio.space/news/former-spac-sponsor-sues-silexion-tel-aviv-note-conversions/) Defendants: Silexion, chairman and CEO Ilan Hadar, and CFO Mirit Horenshtein Hadar. Moringa Sponsor disputes how Silexion converted part of a $3,433 thousand note into shares and alternatively demands cash; Silexion says it complied with the note. 8. 2026-05-28 Listings [Silexion completes 1-for-10 reverse split, its third since late 2024](https://aibio.space/news/silexion-completes-1-10-reverse-split-third-since-late-2024/) Silexion's 1-for-10 reverse share split took effect after the close of trading on May 28, 2026, and the company's warrants were repriced ten-fold with it. By autumn the company was asking shareholders for another split. 9. 2025-09-25 Listings [Silexion Therapeutics regains Nasdaq equity and bid-price compliance](https://aibio.space/news/silexion-therapeutics-regains-nasdaq-equity-bid-price-compliance/) Nasdaq's September 23, 2025 letter confirmed that Silexion meets its $2.5 million shareholders' equity rule and its $1.00 bid-price rule. The company is now under a mandatory panel monitor until September 23, 2026, and one more equity failure in that period would lead to a delisting determination. 10. 2025-09-12 Financings [Silexion Therapeutics prices $6.0 million offering at $4.00 per share and warrants](https://aibio.space/news/silexion-therapeutics-prices-6-0-million-offering-4-00-share-warrants/) Silexion priced a $6.0 million public offering at $4.00 per share and warrants, with H.C. Wainwright as exclusive placement agent. Its prospectus says cash was $3.5 million at June 30, 2025 and carries a going-concern warning. ## Silexion Therapeutics at a glance - **Ticker**: SLXN - **Listing**: NASDAQ - **Country**: Israel - **Cash, Jun 30, 2026**: $2.2 million ### Related companies - [Sol-Gel Technologies](https://aibio.space/companies/sol-gel-technologies/) NASDAQ: SLGL - [Rekah Pharmaceutical Industry](https://aibio.space/companies/rekah-pharmaceutical-industry/) TASE: REKA - [EPITOMEE MEDICAL LTD](https://aibio.space/companies/epitomee-medical/) TASE: EPIT - [MediWound](https://aibio.space/companies/mediwound/) NASDAQ: MDWD - [Can-Fite BioPharma](https://aibio.space/companies/can-fite-biopharma/) TASE: CANF - [Purple Biotech](https://aibio.space/companies/purple-biotech/) TASE: PPBT - [Nasus Pharma](https://aibio.space/companies/nasus-pharma/) AMEX: NSRX - [PolyPid](https://aibio.space/companies/polypid/) NASDAQ: PYPD ### Also on NASDAQ - [Hemab Therapeutics Holdings](https://aibio.space/companies/hemab-therapeutics/) COAG - [Scilex Holding](https://aibio.space/companies/scilex/) SCLX - [SeaStar Medical Holding](https://aibio.space/companies/seastar-medical/) ICU - [Rein Therapeutics](https://aibio.space/companies/rein-therapeutics/) RNTX - [BioStem Technologies](https://aibio.space/companies/biostem-technologies/) BSEM - [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) DMAC ## Silexion Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$7.1 million](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/) | [$5.8 million](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/) | | Net income (loss) | [-$11.9 million](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/) | [-$16.5 million](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/) | | Cash from operations | [-$10.8 million](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/) | [-$8.4 million](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/) | | Cash and equivalents | [$6.0 million](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004138/) | [$1.2 million](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $2.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Silexion Therapeutics Did Silexion Therapeutics do a reverse stock split? Our latest story on this, dated Oct 26, 2026: "Silexion shareholders back a 1-for-24 reverse split and more authorized shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/silexion-shareholders-back-1-24-reverse-split-more-authorized-shares/). Was Silexion Therapeutics delisted? Our latest story on this, dated Sep 25, 2026: "Silexion adds bid-price deficiency to pending Nasdaq panel review". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/silexion-adds-bid-price-deficiency-pending-nasdaq-panel-review/). Has Silexion Therapeutics issued a going-concern warning? Our latest story on this, dated Aug 14, 2026: "Silexion had $2.2 million in cash at June 30 and flags going-concern doubt". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/silexion-had-2-2-million-cash-june-30-flags-going-concern-doubt/). Has Silexion Therapeutics raised money recently? Our latest story on this, dated Aug 14, 2026: "Silexion had $2.2 million in cash at June 30 and flags going-concern doubt". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/silexion-had-2-2-million-cash-june-30-flags-going-concern-doubt/). Has Silexion Therapeutics received a Nasdaq deficiency notice? Our latest story on this, dated Sep 25, 2026: "Silexion adds bid-price deficiency to pending Nasdaq panel review". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/silexion-adds-bid-price-deficiency-pending-nasdaq-panel-review/). Is Silexion Therapeutics involved in a lawsuit? Our latest story on this, dated Jun 22, 2026: "Former SPAC sponsor sues Silexion in Tel Aviv over note conversions". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/former-spac-sponsor-sues-silexion-tel-aviv-note-conversions/). What is the ticker symbol of Silexion Therapeutics? Silexion Therapeutics Corp trades under the ticker SLXN on NASDAQ. Where is Silexion Therapeutics listed? Silexion Therapeutics Corp is listed on NASDAQ. What is the SEC CIK of Silexion Therapeutics? The SEC Central Index Key (CIK) for Silexion Therapeutics Corp is 2022416. Its filings are on SEC EDGAR. How many shares does Silexion Therapeutics have outstanding? 5,560,256 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Silexion Therapeutics listed under? Our directory records Silexion Therapeutics Corp under Israel. What does Silexion Therapeutics do? Our directory classifies Silexion Therapeutics Corp as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Silexion Therapeutics? The ISIN recorded for Silexion Therapeutics Corp is KYG1281K1489. Does aibio.space cover Silexion Therapeutics? aibio.space lists Silexion Therapeutics Corp among 2,820 public biotech companies and publishes its news here as stories appear. Where is Silexion Therapeutics incorporated? SEC records list its state or country of incorporation as E9. ## Investor discussion: Silexion Therapeutics Members talk about Silexion Therapeutics (SLXN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Silexion Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-28 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004894/zk2636266.htm) 2. 2026-10-26 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004849/zk2636262.htm) 3. 2026-10-05 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004708/zk2636195.htm) 4. 2026-09-28 Financing Silexion signed an induced Series E warrant-exercise agreement with new Series F and G warrants. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004645/zk2636167.htm) 5. 2026-09-25 Listing notice Nasdaq added a bid-price deficiency to the panel review. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004609/zk2636161.htm) 6. 2026-09-25 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004606/zk2636159.htm) 7. 2026-09-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004609/zk2636161.htm) 8. 2026-09-24 Listing hearing The company appeared before a Nasdaq panel; no final favorable ruling is verified. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004708/zk2636195.htm) 9. 2026-08-24 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004243/zk2636005.htm) 10. 2026-08-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004223/zk2635995.htm) 11. 2026-08-18 Listing notice Nasdaq issued a new equity-deficiency delisting determination; the company planned an appeal. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004223/zk2635995.htm) 12. 2026-08-14 Going concern The second-quarter report retained substantial doubt and a funding estimate through the fourth quarter. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004138/zk2635847.htm) 13. 2026-08-14 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004145/zk2635968.htm) 14. 2026-08-13 Financing Silexion consummated the August public offering. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004122/zk2635949.htm) 15. 2026-08-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004128/exhibit_99-1.htm) 16. 2026-08-07 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326003961/zk2635892.htm) 17. 2026-08-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326003761/zk2635816.htm) 18. 2026-08-01 Leadership Amnon Peled left the board for personal reasons; Avner Lushi filled the audit-committee vacancy. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326003761/zk2635816.htm) 19. 2026-07-21 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326003551/zk2635714.htm) 20. 2026-06-12 Financing The company filed a Form S-3 registration statement; filing alone is not a cash receipt. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326003174/zk2635528.htm) 21. 2026-06-12 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326003174/zk2635528.htm) 22. 2026-05-29 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/zk2635442.htm) 23. 2026-05-28 Reverse split The one-for-ten reverse split became effective after market close; adjusted trading began on 2026-05-29. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/zk2635442.htm) 24. 2026-05-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002900/exhibit_99-1.htm) 25. 2026-05-18 Financing The company completed the May induced warrant exercise, as described in the later voting report. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326003551/zk2635714.htm) 26. 2026-05-15 Financing Silexion signed an induced warrant-exercise agreement with replacement Series C and D warrants. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002739/zk2635351.htm) 27. 2026-05-15 Going concern The periodic filing included going-concern substantial-doubt language; this event does not carry it forward as current. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002744/zk2635243.htm) 28. 2026-05-05 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/zk2635202.htm) 29. 2026-04-09 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002037/zk2635046.htm) 30. 2026-03-30 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/2022416/000117891326001876/zk2634998.htm) ## Investor questions about Silexion Therapeutics ### How much cash did the latest quarterly statement report? Cash and equivalents were $2.229 million at 2026-06-30, with another $91,000 classified as restricted cash. These are dated balances, not current cash. Source ### What runway did management estimate? Management projected funding through the fourth quarter of 2026 under its current business plan. This forecast does not remove the substantial-doubt warning. Source ### Is SLXN facing Nasdaq delisting risk? Yes. An equity deficiency and a later bid-price deficiency were before the hearing panel; the opened materials do not establish a final favorable decision. Source ### Has an OTC transfer or final delisting been verified? No completed transfer or final removal was verified. The September notice said the ordinary shares would continue trading on the Nasdaq Capital Market at that time. Source ### What is the next stated shareholder meeting date? The company adjourned its extraordinary meeting to 2026-10-26 without conducting business. The two proposals, a share capital increase and a reverse split, had not been voted on at that point. Source ### Did September shareholders approve another reverse split? No. The meeting rejected both proposals, including the proposed one-for-fifteen split. Source ### Did Silexion complete a reverse split in May? Yes. A one-for-ten split took effect after market close on 2026-05-28, with adjusted trading on 2026-05-29. Source ### Was the August public offering completed? The company reported consummation on 2026-08-13 and approximately $2.5 million gross proceeds. Those receipts exclude potential future warrant exercise proceeds. Source ### What is the sponsor litigation about? The complaint disputes conversion of sponsor-note debt into shares and seeks alternative monetary relief. Silexion says the claims lack merit; no court finding is asserted. Source ### Is the reported insider sale described as a tax transaction? The Form 4 describes Mitchell Shirvan's 2026-03-26 sale of 22,818 shares as a tax sale-to-cover. These are historical units as filed before the later May split. Source ### Who is the latest proxy's five-percent holder? The proxy lists Moringa Sponsor, LP and related persons at 1,954,241 beneficially owned shares and 13.5%, using its stated date and definitions. The sponsor disputes some converted-share ownership. Source ### Who signed the latest annual audit? Kesselman & Kesselman signed the audit report and states it has served since 2023. No subsequent auditor change was verified. Source ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SLXN on TradingView](https://www.tradingview.com/symbols/NASDAQ-SLXN/). ## SEC filings and registration - **SEC name**: Silexion Therapeutics Corp - **CIK**: 2022416 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: SLXN (Nasdaq), SLXNW (Nasdaq) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 12 ABBA HILLEL ROAD, RAMAT GAN, Israel, 5250606 - **Phone**: 972-8-6286005 - **Shares outstanding**: 5,560,256 as of 2026-08-13 (10-Q filed 2026-08-14) - **Former names**: Biomotion Sciences ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004708/zk2636195.htm) filed 2026-10-05 - [8-K](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004666/zk2636171.htm) filed 2026-09-30 - [8-K](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004645/zk2636167.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004628/zk2636165.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004609/zk2636161.htm) filed 2026-09-25 - [8-K](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004604/zk2636155.htm) filed 2026-09-25 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004243/zk2636005.htm) filed 2026-08-24 - [8-K](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004223/zk2635995.htm) filed 2026-08-21 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002022416), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Silexion Therapeutics Corp is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SLXN, recorded under Israel. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Silexion Therapeutics Corp - **Ticker**: SLXN - **Listing**: NASDAQ - **Country or territory**: Israel - **Business scope**: Pharmaceuticals: Major - **ISIN**: KYG1281K1489 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SLXN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/silexion-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Silexion Therapeutics (SLXN) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/silexion-therapeutics/